Rofecoxib: A Review of its Use in the Management of Osteoarthritis, Acute Pain and Rheumatoid Arthritis

Matheson, A.J.; Figgitt, D.P.
April 2001
Drugs;Apr2001, Vol. 61 Issue 6, p833
Academic Journal
Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day. Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin. In well-controlled clinical trials, rofecoxib 12.5 to 500 mg/day has been evaluated for its efficacy in the treatment of osteoarthritis, acute pain and rheumatoid arthritis [lower dosages (5 to 125 mg/day) were generally used in the chronic pain indications]. In the treatment of patients with osteoarthritis, rofecoxib was more effective in providing symptomatic relief than placebo, paracetamol (acetaminophen) and celecoxib and was similar in efficacy to ibuprofen, diclofenac, naproxen and nabumetone. Overall, both the physician's assessment of disease status and the patient's assessment of response to therapy tended to favour rofecoxib. In patients with postsurgical dental pain, pain after spinal fusion or orthopaedic surgery, or primary dysmenorrhoea, rofecoxib provided more rapid and more sustained pain relief and reduced requirements for supplemental morphine use after surgery than placebo. Rofecoxib was more efficacious than celecoxib in patients with acute dental pain and pain after spinal fusion surgery, although celecoxib may have been used at a subtherapeutic dose. In comparison with traditional nonsteroidal anti-inflammatory drugs (NSAIDs) ibuprofen, diclofenac and naproxen sodium, rofecoxib was similar in efficacy in the treatment of acute pain. Although naproxen sodium provided more rapid pain relief than rofecoxib in patients with primary dysmenorrhoea, the reverse was true after orthopaedic surgery: rofecoxib provided more rapid pain relief and less supplemental morphine was needed. Rofecoxib was as effective as naproxen in providing symptomatic relief for over 8700 patients with rheumatoid arthritis. Compared with traditional NSAID therapy, rofecoxib had a significantly lower incidence of endoscopically confirmed gastroduodenal ulceration and, in approximately 13 000 patients with osteoarthritis and rheumatoid arthritis, a lower incidence of gastrointestinal (GI) adverse events. Rofecoxib was generally well tolerated in all indications with an overall tolerability profile similar to traditional NSAIDs. The most common adverse events in rofecoxib recipients were nausea, dizziness and headache. In conclusion, rofecoxib is at least as effective as traditional NSAID therapy in providing pain relief for both chronic and acute pain conditions. Rofecoxib provides an alternative treatment option to traditional NSAID therapy in the management of symptomatic pain relief in patients with osteoarthritis. Initial data from patients with primary dysmenorrhoea and postoperative pain are promising and further trials may confirm its place in the treatment of these indications. Rofecoxib has also shown promising results in patients with rheumatoid arthritis and is likely to become a valuable addition to current drug therapy for this patient population. Importantly, rofecoxib is associated with a lower incidence of GI adverse events than traditional NSAIDs making it a primary treatment option in patients at risk of developing GI complications or patients with chronic conditions requiring long term treatment.


Related Articles

  • COX-2 inhibitors may differ in their effects on systolic blood pressure.  // Geriatrics;Jun2001, Vol. 56 Issue 6, p53 

    Reports on a comparative study on the effects of cyclo-oxygenase-2 inhibitors celecoxib and rofecoxib on systolic blood pressure (SBP) and development of edema when used to treat osteoarthritis in older patients with hypertension. Impact of celecoxib and rofecoxib on SBP control and rates of...

  • COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents. Supuran, Claudiu T.; Casini, Angela; Mastrolorenzo, Antonio; Scozzafava, Andrea // Mini Reviews in Medicinal Chemistry;Aug2004, Vol. 4 Issue 6, p625 

    The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anti-carbonic anhydrase, diuretic, hypoglycaemic, antithyroid, protease inhibitory and anticancer activity among others. A recently developed class of pharmacological...

  • New N-aryl-4-(methysulfony)aminobenzenesulfonamides as Selective COX-2 inhibitors. Moallem, Seyed Adel; Hadizadeh, Farzin; Yavar, Isa // Journal of Biological Sciences;2011, Vol. 11 Issue 8, p496 

    A group of N-aryl- 4-amethylsulfonyl)aminobenzenesulfonamides, possessing a (methylsulfonyl) amino pharmacophore at the para-position of the one phenyl ring, in conjunction with another substituted phenyl ring (4-F, 4-H, 4-Me, 4-OMe) were evaluated as selective cyclooxygenase-2 (COX-2)...

  • Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis. Boyce, Eric G.; Breen, Gail A. // Formulary;May99, Vol. 34 Issue 5, p405 

    Focuses on the use of Celecoxib, a nonsteroidal anti-inflammatory drug and cyclooxygenase-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis. Sulfonamide structural component of Celecoxib; Lower risks of severe gastrointestinal and platelet effects of Celecoxib; Other...

  • COX-2 inhibitors.  // Mayo Clinic Health Letter;Apr1999, Vol. 17 Issue 4, p7 

    Discusses the use of super aspirins, which refers to a class of drugs called COX-2 inhibitors, to treat osteoarthritis. Most commonly used medications to treat osteoarthritis; Side effects; Two versions of cyclooxygenase (COX); Factors to consider before using COX-2. INSET: Are they really...

  • Rare head-to-head drug studies.  // Patient Care;9/15/2000, Vol. 34 Issue 17, p11 

    Cites the results of a study comparing the cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, both indicated for osteoarthritis. Absence of difference in pain reduction; Increase of blood pressure in subjects taking rofexocib.

  • Foreword. Huskisson, Edward C. // Inflammopharmacology;2002, Vol. 10 Issue 3, p157 

    Explains that the development of COX-2 inhibitors should cause doctors to abandon old drugs. Illustration on the effectiveness of using COX-2 inhibitors together with older drugs to relieve patients of suffering; Information on NSAIDS and COX-1 inhibitors.

  • Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition. de Leval, Xavier; Delarge, Jacques; Somers, Fabian; de Tullio, Pascal; Henrotin, Yves; Pirotte, Bernard; Dogne, Jean-Michel // Current Medicinal Chemistry;Oct2000, Vol. 7 Issue 10, p1041 

    Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physio- logical processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a...

  • New Trends in Dual 5-LOX / COX Inhibition. de Leval, Xavier; Julemont, Fabien; Delarge, Jacques; Pirotte, Bernard; Dogne, Jean-Michel // Current Medicinal Chemistry;May2002, Vol. 9 Issue 9, p941 

    Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. The interest of developing such compounds is supported by a large number of pharmacological studies. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics